Glycihal G 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Glycihal G 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Regular monitoring of blood glucose, renal function, and periodic assessment of liver function tests is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glycihal G 2 Tablet PR should be used under medical supervision to optimize glycemic control and minimize complications associated with diabetes mellitus.